SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?

Detalles Bibliográficos
Autores principales: Patoulias, Dimitrios, Michailidis, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2022
Materias:
Hot Topic Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396330/
https://www.ncbi.nlm.nih.gov/pubmed/36062276
http://dx.doi.org/10.14218/JCTH.2022.00278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396330/
https://www.ncbi.nlm.nih.gov/pubmed/36062276
http://dx.doi.org/10.14218/JCTH.2022.00278

Ejemplares similares